Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Martha Arellano, Emory University
ClinicalTrials.gov Identifier:
NCT00548847
First received: October 22, 2007
Last updated: August 13, 2015
Last verified: August 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: May 2016
  Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)